cART op basis van proteaseremmers vermindert respons en geeft meer bijwerkingen bij chemotherapie tegen lymfomen dan cART op basis van niet-nucleoside reversetranscriptaseremmers

Autor: Sombogaard, F., Crul, M., Van Den Berk, G. E.L., Kerver, E. D., Franssen, E. J.F.

Publikováno v: Pharmaceutisch Weekblad, 148(23), 78-82. Kon. Ned. Mij. ter Bevordering der Pharmacie (KNMP)

OBJECTIVE: To investigate the incidence of dose adjustments, delays and discontinuation of chemotherapy and the incidence of antineoplastic drug related toxicity in patients treated for lymphoma combined with cART, as well as differences between pati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=narcis______::526353a9fdf443b771785d61feda189c
https://research.vumc.nl/en/publications/d20696e4-6141-46d0-a816-8202d9d982c9

Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography

Autor: Hendrikse, N. H., Schinkel, A. H., De Vries, E. G.E., Fluks, E., Van Der Graaf, W. T.A., Willemsen, A. T.M., Vaalburg, W., Franssen, E. J.F.

Publikováno v: Hendrikse, N H, Schinkel, A H, De Vries, E G E, Fluks, E, Van Der Graaf, W T A, Willemsen, A T M, Vaalburg, W & Franssen, E J F 1998, ' Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography ', British Journal of Pharmacology, vol. 124, no. 7, pp. 1413-1418 . https://doi.org/10.1038/sj.bjp.0701979
British Journal of Pharmacology, 124(7), 1413-1418. Wiley-Blackwell

1. Homozygously mdr1a gene disrupted mice (mdr1a(-/-) mice) and wild type mice (mdr1a(+/+) mice) were used to develop a method for P-glycoprotein (P-gp) function imaging non-invasively and to study the effect of a P-gp reversal agent on its function

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::5fed579c65d983aeda848ed3438d3f2a
https://research.vumc.nl/en/publications/9d4131ab-06d5-4c72-a444-57f9df875d37

109. Turnover studies with ¹²³I-labelled serum amyloid P component in systemic amyloidosis and assessment of its clinical value.

Autor: Jager, P. L., Hazenberg, B. P.C., Franssen, E. J.F., van Rijswijk, M. H., Piers, D. A.

Publikováno v: Nuclear Medicine Communications; Apr1997, Vol. 18 Issue 4, p322-322, 1p